Keyphrases
Natural Killer Cells
97%
Memory-like
70%
Metastatic Melanoma
46%
Melanoma
43%
Cell Response
36%
Chimeric Antigen Receptor T Cells (CAR-T)
33%
Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS)
23%
Photothermal Therapy
23%
Phase II Study
23%
Recurrent Glioblastoma
23%
Doxorubicin
23%
Neuro-oncology
23%
Human NK Cells
23%
Overall Survival
20%
COVID-19
18%
Advanced Melanoma
17%
Cetuximab
16%
Targeted Therapy
15%
COVID-19 Impact
15%
Circulating Tumor DNA (ctDNA)
15%
Leukemia
14%
BRAFV600
14%
NK Cell Activity
14%
Multiple Myeloma
13%
Clinical Trials
13%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
13%
Adaptive NK Cells
13%
Adoptive Cell Therapy
12%
Predictive Biomarker
12%
Antitumor Effect
12%
Cell Differentiation
12%
Myeloma
12%
Melanoma Patients
12%
Daggers
11%
Clinical Characterization
11%
Colitis
11%
Real-world Experience
11%
Melanoma Brain Metastases
11%
Hematopoietic Cell Transplantation
11%
Cancer-specific
11%
Anti-programmed Death 1
11%
DNA Assay
11%
Donor-derived
11%
Multiplexed Immunohistochemistry
11%
Neurofilament Light (NF-L)
11%
Chain Level
11%
COVID-19 Inpatients
11%
MEK Inhibitor (MEKi)
11%
NK Cell Therapy
11%
Melanoma Treatment
11%
Medicine and Dentistry
Natural Killer Cell
77%
Melanoma
59%
Immunotherapy
43%
Metastatic Melanoma
30%
Neoplasm
26%
Natural Killer Cell Response
25%
Chimeric Antigen Receptor
24%
COVID-19
23%
Neuro-Oncology
23%
Malignant Neoplasm
20%
Circulating Tumor DNA
19%
Cetuximab
18%
Diseases
18%
Clinical Trial
17%
Immune Checkpoint Inhibitor
14%
Overall Survival
14%
T Cell
14%
CD8 Antigen
14%
Multiple Myeloma
14%
Head and Neck Squamous Cell Carcinoma
13%
Cell Differentiation
13%
Toxicity and Intoxication
12%
Myeloma
12%
Radiation Therapy
12%
Patient with Leukemia
12%
Gene Expression Profiling
11%
Effector Cell
11%
Mitogen Activated Protein Kinase Inhibitor
11%
Combined Therapy
11%
Whole Body Radiation
11%
Neurofilament
11%
Merkel Cell Carcinoma
11%
Doxorubicin
11%
Pembrolizumab
11%
Stereotactic Body Radiation Therapy
11%
Natural Killer T Cell
11%
4 Iodo 2,5 Dimethoxyamphetamine
11%
Cell Transplantation
11%
Light Chain
11%
Testis Cancer
11%
Brain Metastasis
11%
Immunohistochemistry
11%
Melanoma Cell
11%
Colitis
11%
DNA Determination
11%
Head and Neck Cancer
11%
Interleukin 7
11%
Skin Carcinoma
11%
Glioblastoma
11%
Hematopoietic Cell
11%
Immunology and Microbiology
Natural Killer Cell
100%
Chimeric Antigen Receptor
27%
Natural Killer Cell Response
25%
Cytokine
18%
Chimeric Antigen Receptor T-Cell Therapy
15%
Effector Cell
14%
Immunotherapy
14%
Multiple Myeloma
13%
Cell Differentiation
12%
Cell Activation
12%
Interleukin 7
11%
Natural Killer T Cell
11%
Neck
11%
Overall Survival
11%
Talimogene Laherparepvec
11%
Cell Transplantation
11%
CD8
11%
Hematopoietic Cell
11%
T Cell
11%
B Cell Maturation Antigen
10%
Squamous Cell
9%
Progression Free Survival
7%
Interleukin 15
7%
Xenograft
6%
Chimeric Antigen Receptor T-Cell
6%
Interleukin 12
6%
Cetuximab
6%
Cytotoxicity
5%
